After Hours Summary: PIR +8%, SCHN +2% following earnings/guidance, AEGR +36.5% on Juxtapid Japan approval... PRGS -10% following earnings/guidance/CFO news, ITCI -67% after trial failed to meet primary endpointAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: PIR +8.2%, SCHN +2.2%
Companies trading higher in after hours in reaction to news: AEGR +36.5% (announces Juxtapid capsules approved in Japan for the treatment of homozygous familial hypercholesterolemia), EBIO +1.7% (modestly higher after 10% owner / Director Leslie Dan filed 13D confirming 14.8% active stake), HIMX +1.4% (initiated with Buy ratings at Roth Capital), IBKR +0.6% (Bloomberg reporting that Scottrade is exploring a sale), SRPT +0.5% (ticking higher, announces first patient dosed in Phase III clinical trial of SRP-4045 and SRP-4053 for the treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 skipping), AMTD +0.4% (higher in after hours on Bloomberg report that the company may be interested in acquiring Scottrade), AMGN +0.4% (light volume; announces erenumab 'significantly reduces' monthly migraine days in patients with episodic migraine in first phase 3 study), AMBA +0.3% (ticking higher - initiated with Buy ratings at Roth Capital)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: PRGS -9.9% (also appoints Kurt Abkemeier as CFO succeeding Chris Perkins; initiates quarterly dividend)
Companies trading lower in after hours in reaction to news: ITCI -67.2% (announces top-line results from the second Phase 3 Trial of ITI-007 in patients with Schizophrenia), ATNM -14.7% (announces an underwritten public offering of common stock), MSON -4.5% (thinly traded - notified SEC/DoJ that it may have had knowledge of certain business practices of independent Chinese entity that distributes its products, which practices raise questions under FCPA), NSPR -3.7% (announces a 1-for-25 reverse split of its common stock), ALNY -2.2% (presents clinical and non-clinical data demonstrating continued rnai platform optimization and leadership in the development of RNA-based therapeutics at 12th annual meeting of the Oligonucleotide Therapeutics Society), DTE -1.2% (announces 12 mln equity units offering), VRTX -0.4% (confirms FDA approval of Orkambi for use in children with cystic fibrosis ages 6 through 11 who have 2 copies of the F508del mutation; lowers FY16 Orkambi rev guidance), RIG -0.2% (light volume - Carl Icahn confirms lowered active stake to 1.5%)